Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

BACKGROUND: Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in patients who do not respond to steroids. We assessed the effect of early SIT intro...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Abu-Sbeih, Hamzah, Ali, Faisal S., Wang, Xuemei, Mallepally, Niharika, Chen, Ellie, Altan, Mehmet, Bresalier, Robert S., Charabaty, Aline, Dadu, Ramona, Jazaeri, Amir, Lashner, Bret, Wang, Yinghong
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444537/
https://ncbi.nlm.nih.gov/pubmed/30940209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0577-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares